Phase III Results Position Selecta/Sobi’s SEL-212 As Tough Competition For Krystexxa In Gout

 
• By Alaric DeArment

Analysts pointed to SEL-212’s more favorable dosing and adverse event profile with fewer limitations that may harm compliance versus Krystexxa from Horizon, which is soon to be acquired by Amgen.

Selecta and Sobi posted positive topline results from their Phase III trials of SEL-212 in chronic refractory gout • Source: Shutterstock

More from Clinical Trials

More from R&D